Cargando…
Mono-symptomatic Fabry disease in a population with mild-to-moderate left ventricular hypertrophy
Fabry disease (FD) results from a deficiency in the exoglycohydrolase, α-galactosidase A (AGA), an enzyme required for the sequential degradation of glycosphingolipids, which consequently accumulate in the lysosomes of affected cells. An X-linked inherited metabolic disorder, FD has a high incidence...
Autores principales: | Fuller, Maria, Perry, Rebecca, Saiedi, Madiha, Fletcher, Janice M., Selvanayagam, Joseph B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733018/ https://www.ncbi.nlm.nih.gov/pubmed/33335842 http://dx.doi.org/10.1016/j.ymgmr.2020.100697 |
Ejemplares similares
-
Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis
por: Yousef, Zaheer, et al.
Publicado: (2013) -
Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy
por: Sadasivan, Chandu, et al.
Publicado: (2020) -
Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy
por: Kim, Woo-Shik, et al.
Publicado: (2019) -
Screening for Fabry Disease in Left Ventricular Hypertrophy:
Documentation of a Novel Mutation
por: Baptista, Ana, et al.
Publicado: (2015) -
Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)